Kuehne+Nagel delivers Covid-19 vaccine to Dominican Republic

  • March 1, 2021
  • Steve Rogerson

Kuehne+Nagel is using active temperature-controlled containers to transport the Sinovac Covid-19 vaccine from China to the Dominican Republic.

The Swiss logistics company helped Sinovac Biotech, a Chinese biopharmaceutical company, fulfil its first Covid-19 vaccine shipment from Beijing to the Dominican Republic.

Sinovac is one of the global players in Covid-19 vaccine research and development. To date, the vaccine has been approved for emergency use or conditional marketing authorisation in more than 20 countries, including China, Brazil, Indonesia, Turkey and Chile.

The pilot shipment containing 768,000 vials of Covid-19 vaccine was stored in active temperature-controlled containers and arrived safely in Santo Domingo, the capital of the Dominican Republic last week. The shipment was closely monitored and compliant with the most stringent standards to guarantee product integrity.

“The Dominican Republic is 14,000km away from our factory in Beijing,” said Helen Yang, general manager of Sinovac Biotech. “During the on-going pandemic, there are very few carriers connecting to this remote destination. However, Kuehne+Nagel responded to us with a feasible solution in just a short span of twelve hours. Even during the Chinese New Year holidays, the Kuehne+Nagel team was diligently preparing this shipment. We look forward to a collaborative partnership with Kuehne+Nagel.”

Prior to the shipment, Kuehne+Nagel fulfilled multiple crucial assignments for Sinovac, including an air charter from Beijing to Turkey for a door-to-door delivery of nearly a quarter-million flu vaccines. Kuehne+Nagel also helped with the shipment of Hepatitis A vaccine to Guatemala in South America as well as making nucleic acid detection kits available to people in Indonesia.

“We couldn’t be prouder to having started shipments of Sinovac Covid-19 vaccine,” said Siewloong Wong, president of Kuehne+Nagel in Asia Pacific. “At Kuehne+Nagel, we leverage our global pharma and healthcare network and expertise to bring the Sinovac vaccine to the market. We truly appreciate the trust that Sinovac has bestowed upon us.”

With offices all over the world, 240 GxP-certified operations and more than 3000 dedicated pharma and healthcare specialists, Kuehne+Nagel says it has the capacity, the ability and the responsibility to play a vital role in the global distribution of Covid-19 vaccine.